Abuse of Regulatory Procedures in the Pharmaceutical Sector Developments Since the General Court’s Judgment in AstraZeneca

Patrick Harrison, Kristina Nordlander, Jul 27, 2012

In June 2005, the European Commission issued a decision finding that AstraZeneca had breached Article 102 TFEUby engaging in conduct aimed at blocking or delaying market access for generic alternatives to its blockbuster Losec product. The decision was highly controversial at the time, and the Commission acknowledged that it was making “novel” findings of abuse of regulatory procedures, but, in July 2010, the EU’s General Cou